L
Laura Tandeske
Researcher at Novartis
Publications - 9
Citations - 141
Laura Tandeske is an academic researcher from Novartis. The author has contributed to research in topics: Antigen & Epitope. The author has an hindex of 5, co-authored 9 publications receiving 141 citations. Previous affiliations of Laura Tandeske include Chiron Corporation.
Papers
More filters
Journal ArticleDOI
Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses.
Michael Vajdy,Mark J. Selby,Angelica Medina-Selby,Doris Coit,Hall John A,Laura Tandeske,David Y. Chien,Celine Hu,Domenico Rosa,Manmohan Singh,Jina Kazzaz,Steve Nguyen,Steve Coates,Philip Ng,Sergio Abrignani,Yin-Ling Lin,Michael Houghton,Derek T. O'Hagan +17 more
TL;DR: The data suggest that the HCV polyprotein delivered with adjuvants induces broad B- and T-cell responses and could be a vaccine candidate against HCV.
Patent
Hcv antigen/antibody combination assay
David Y. Chien,Phillip Arcangel,Laura Tandeske,Carlos George-Nasciemento,Doris Coit,Angelica Medina-Selby +5 more
TL;DR: An HCV core antigen and NS3/4a antibody combination assay that can detect both HCV antigens and antibodies present in a sample using a single solid matrix, as well as immunoassay solid supports for use in the assay is provided in this paper.
Journal ArticleDOI
Design of Novel Conformational and Genotype-Specific Antigens for Improving Sensitivity of Immunoassays for Hepatitis C Virus-Specific Antibodies
Sansan Lin,Phillip Arcangel,Angelica Medina-Selby,Doris Coit,Philip Ng,Steve Nguyen,Colin S. McCoin,Alex Gyenes,Celine Hu,Laura Tandeske,Bruce Phelps,David Y. Chien +11 more
TL;DR: An HCV antibody assay that employs a conformational protein, NS3NS4a PI (with functional protease and helicase activities), and a linear fusion protein, multiple-epitope fusion antigen 7.1 or 7.2 may have the potential to replace current HCV immunoassays for better sensitivity.
Patent
Immunoassays for anti-hcv antibodies
David Y. Chien,Phillip Arcangel,Laura Tandeske,Carlos George-Nascimento,Doris Coit,Angelica Medina-Selby +5 more
TL;DR: In this paper, an NS3/4a conformational epitope and a multiple epitope fusion antigen fusion antigen are provided, as well as immunoassay solid supports for use with the immunoASSays.
Patent
HCV multiple epitope fusion antigens with modified proteolytic cleavage sites and uses thereof
David Y. Chien,Doris Coit,Carlos George-Nascimento,Sansan Lin,Angelica Medina-Selby,Laura Tandeske +5 more
TL;DR: In this paper, modified HCV multiple epitope fusion antigens (MEFAs) are described, which include modified sequences such that proteolytic cleavage of the MEFAs by HCV NS3 protease is inhibited.